Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| Yesterday 3:07 PM View:  | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | Yesterday | Option Exercise | 12,900 | $1.55 | $19,995.00 | 4% 330.74K to 343.63K | |
| 15-Oct-24 5:59 PM View: | Aguilar-Cordova Estuardo 10% Owner | Candel Therapeutics, Inc. (CADL) | 15-Oct-24 | Market Sale | 10,412 | $6.03 | $62,784.40 | (< 1%) 6.06M to 6.05M | (15%) |
| 15-Oct-24 5:59 PM View: | Aguilar-Cordova Estuardo 10% Owner | Candel Therapeutics, Inc. (CADL) | 14-Oct-24 | Market Sale | 15,000 | $6.02 | $90,300.00 | (< 1%) 6.08M to 6.06M | (15%) |
| 15-Oct-24 5:59 PM View: | Aguilar-Cordova Estuardo 10% Owner | Candel Therapeutics, Inc. (CADL) | 11-Oct-24 | Market Sale | 15,000 | $6.05 | $90,750.00 | (< 1%) 6.09M to 6.08M | (14%) |
| 19-Jul-24 8:29 AM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 17-Jul-24 | Market Sale | 22,528 | $6.47 | $145,815.00 | (6%) 353.26K to 330.74K | (7%) |
| 19-Jul-24 8:28 AM View: | Schoch Charles See Remarks | Candel Therapeutics, Inc. (CADL) | 17-Jul-24 | Market Sale | 9,884 | $6.47 | $63,975.20 | (14%) 72.4K to 62.52K | (7%) |
| 19-Jul-24 8:31 AM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 17-Jul-24 | Market Sale | 14,851 | $6.47 | $96,124.60 | (9%) 160.9K to 146.05K | (7%) |
| 19-Jul-24 8:24 AM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 17-Jul-24 | Market Sale | 14,051 | $6.47 | $90,946.50 | (8%) 174.01K to 159.96K | (7%) |
| 19-Jul-24 8:26 AM View: | Nichols Garrett Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 17-Jul-24 | Market Sale | 10,875 | $6.47 | $70,389.50 | (9%) 125.36K to 114.48K | (7%) |
| 15-Jul-24 8:36 AM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 11-Jul-24 | Market Sale | 13,330 | $5.97 | $79,625.40 | (8%) 174.23K to 160.9K | (16%) |
| 15-Jul-24 8:30 AM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 11-Jul-24 | Market Sale | 12,645 | $5.97 | $75,533.60 | (7%) 186.66K to 174.01K | (16%) |
| 15-Jul-24 8:32 AM View: | Nichols Garrett Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 11-Jul-24 | Market Sale | 9,769 | $5.97 | $58,354.10 | (7%) 135.13K to 125.36K | (16%) |
| 15-Jul-24 8:35 AM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 11-Jul-24 | Market Sale | 20,293 | $5.97 | $121,218.00 | (5%) 373.56K to 353.26K | (16%) |
| 15-Jul-24 8:34 AM View: | Schoch Charles See Remarks | Candel Therapeutics, Inc. (CADL) | 11-Jul-24 | Market Sale | 8,897 | $5.97 | $53,145.30 | (11%) 81.3K to 72.4K | (16%) |
| 30-Nov-23 5:00 PM View: | Amello Jason Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-23 | Payment of Exercise | 20,153 | $0.90 | $18,137.70 | (9%) 222.16K to 202.01K | |
| 30-Nov-23 5:00 PM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 28-Nov-23 | Payment of Exercise | 43,443 | $0.90 | $39,098.70 | (10%) 417.0K to 373.56K | |
| 30-Nov-23 5:00 PM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-23 | Payment of Exercise | 17,328 | $0.90 | $15,595.20 | (9%) 191.56K to 174.23K | |
| 30-Nov-23 5:00 PM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-23 | Payment of Exercise | 19,748 | $0.90 | $17,773.20 | (10%) 206.41K to 186.66K | |
| 30-Nov-23 5:00 PM View: | Nichols Garrett Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-23 | Payment of Exercise | 12,175 | $0.90 | $10,957.50 | (8%) 147.3K to 135.13K | |
| 28-Nov-23 4:30 PM View: | Amello Jason Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 26-Nov-23 | Grant | 125,717 | -- | -- | 130% 96.44K to 222.16K | |
| 28-Nov-23 4:30 PM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 26-Nov-23 | Grant | 180,108 | -- | -- | 76% 236.89K to 417.0K | |
| 28-Nov-23 4:30 PM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 26-Nov-23 | Grant | 104,516 | -- | -- | 120% 87.04K to 191.56K | |
| 28-Nov-23 4:30 PM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 26-Nov-23 | Grant | 112,790 | -- | -- | 120% 93.61K to 206.41K | |
| 28-Nov-23 4:30 PM View: | Nichols Garrett Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 26-Nov-23 | Grant | 88,822 | -- | -- | 152% 58.48K to 147.3K | |
| 12-Dec-22 4:25 PM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 09-Dec-22 | Purchase | 10,358 | $1.93 | $19,990.90 | 345% 3.0K to 13.36K | |
| 12-Dec-22 4:25 PM View: | Martell Christopher Director | Candel Therapeutics, Inc. (CADL) | 09-Dec-22 | Purchase | 23,950 | $1.92 | $45,984.00 | 19% 128.05K to 152.0K | |
| 12-Dec-22 4:25 PM View: | Amello Jason Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 09-Dec-22 | Purchase | 2,468 | $1.93 | $4,763.24 | 80% 3.1K to 5.57K | |
| 12-Dec-22 4:25 PM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 09-Dec-22 | Purchase | 12,935 | $1.92 | $24,835.20 | 46% 28.05K to 40.98K | |
| 12-Dec-22 4:25 PM View: | Papa Joseph C Director | Candel Therapeutics, Inc. (CADL) | 09-Dec-22 | Purchase | 35,018 | $1.94 | $67,934.90 | 1162% 3.01K to 38.03K | |
| 12-Dec-22 4:30 PM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 1,238 | $1.61 | $1,993.18 | 83% 1.5K to 2.74K | |
| 12-Dec-22 4:25 PM View: | Martell Christopher Director | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 3,050 | $1.68 | $5,124.00 | 2% 125.0K to 128.05K | |
| 12-Dec-22 4:25 PM View: | Amello Jason Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 3,100 | $1.69 | $5,239.00 | 100% 0 to 3.1K | |
| 12-Dec-22 4:25 PM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 3,050 | $1.70 | $5,185.00 | 12% 25.0K to 28.05K | |
| 12-Dec-22 4:25 PM View: | Papa Joseph C Director | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 3,014 | $1.70 | $5,123.80 | 100% 0 to 3.01K | |
| 12-Dec-22 4:25 PM View: | Tyagarajan Seshu Chief Technology Officer | Candel Therapeutics, Inc. (CADL) | 08-Dec-22 | Private Purchase | 3,000 | $1.69 | $5,070.00 | 100% 0 to 3.0K | |
| 30-Nov-22 6:31 PM View: | Amello Jason Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-22 | Grant | 90,877 | -- | -- | 100% 0 to 90.88K | |
| 30-Nov-22 6:30 PM View: | Tak Paul Peter Chief Executive Officer Director | Candel Therapeutics, Inc. (CADL) | 28-Nov-22 | Grant | 195,906 | -- | -- | 784% 25.0K to 220.91K | |
| 30-Nov-22 6:29 PM View: | Nichols Garrett Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-22 | Grant | 58,479 | -- | -- | 100% 0 to 58.48K | |
| 30-Nov-22 6:30 PM View: | Barone Francesca Chief Scientific Officer | Candel Therapeutics, Inc. (CADL) | 28-Nov-22 | Grant | 90,877 | -- | -- | 6058% 1.5K to 92.38K | |
| 30-Nov-22 6:26 PM View: | Tyagarajan Seshu See Remarks | Candel Therapeutics, Inc. (CADL) | 28-Nov-22 | Grant | 73,684 | -- | -- | 100% 0 to 73.68K | |
| 10-May-22 6:04 PM View: | Aguilar-Cordova Estuardo Director 10% Owner | Candel Therapeutics, Inc. (CADL) | 06-May-22 | Payment of Exercise | 54,074 | $3.65 | $197,370.00 | (2%) 3.23M to 3.17M | |
| 10-May-22 6:07 PM View: | Aguilar Laura K. 10% Owner | Candel Therapeutics, Inc. (CADL) | 06-May-22 | Option Exercise | 171,335 | $1.46 | $250,149.00 | 6% 2.94M to 3.12M | |
| 10-May-22 6:04 PM View: | Aguilar-Cordova Estuardo Director 10% Owner | Candel Therapeutics, Inc. (CADL) | 06-May-22 | Option Exercise | 135,183 | $1.46 | $197,367.00 | 4% 3.09M to 3.23M | |
| 10-May-22 6:07 PM View: | Aguilar Laura K. 10% Owner | Candel Therapeutics, Inc. (CADL) | 06-May-22 | Payment of Exercise | 68,534 | $3.65 | $250,149.00 | (2%) 3.12M to 3.05M | |
| 02-Aug-21 8:02 PM View: | Caffo Nathan Chief Business Officer | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Purchase | 6,000 | $8.00 | $48,000.00 | 100% 0 to 6.0K | |
| 02-Aug-21 8:12 PM View: | Aguilar-Cordova Estuardo Chief Scientific Officer Director | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Conversion | 162,137 | -- | -- | 6% 2.93M to 3.09M | |
| 02-Aug-21 8:04 PM View: | Aguilar Laura K. Chief Medical Officer | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Conversion | 56,096 | -- | -- | 2% 2.89M to 2.94M | |
| 02-Aug-21 8:06 PM View: | Canepa John J Chief Financial Officer | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Purchase | 10,125 | $8.00 | $81,000.00 | 100% 0 to 10.13K | |
| 02-Aug-21 8:12 PM View: | Martell Christopher Director | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Conversion | 283,514 | -- | -- | 100% 0 to 283.51K | |
| 29-Jul-21 9:02 PM View: | Manning Paul B Director | Candel Therapeutics, Inc. (CADL) | 29-Jul-21 | Purchase | 20,000 | $7.30 | $145,944.00 | 56% 36.0K to 56.0K |
